L'effet du guselkumab sur l'inhibition de la progression radiographique chez les patients atteints de rhumatisme psoriasique actif : Protocole d'étude pour APEX, un essai de phase 3b, multicentrique, randomisé, en double aveugle, contrôlé par placebo

Guselkumab was approved for treating the signs and symptoms of active PsA following two Phase 3 global studies, DISCOVER-1 and DISCOVER-2. The Phase 3b APEX study has been designed to address the limitations of DISCOVER-2 and further assess the effects of guselkumab Q4W and Q8W on PsA outcomes.

These outcomes includes clinical efficacy, radiographic progression, and HRQoL, in a biologic-naïve patient population which has been enriched for those more likely to demonstrate radiographic progression.